Positive Results From SEQUOIA Analyses for Zanubrutinib in Treatment-Naive CLL and SLL
In an interim analyses of the phase 3 SEQUOIA trial, zanubrutinib had superior progression-free survival compared with bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
Patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) had superior progression-free survival (PFS) when treated with zanubrutinib (Brukinsa) vs bendamustine and rituximab (B+R), according to an interim analysis of a phase 3 trial.
SEQUOIA is a randomized, multicenter, global phase 3 trial comparing the efficacy and safety of zanubrutinib against B+R in patients with treatment-naive CLL and SLL whose tumor did not exhibit del(17p). The primary end point of the trial was PFS as assessed by independent review committee, and there was a median follow-up of 25.8 months.
The trial has 3 cohorts:
- Cohort 1 has 479 patients randomized 1:1 to receive zanubrutinib or B+R until disease progression or unacceptable toxicity. This cohort does not include patients with del(17p).
- Cohort 2 has 110 patients with del(17p) receiving zanubrutinib as a monotherapy.
- Cohort 3 is currently enrolling patients with del(17p) or pathogenic TP53 variant to receive zanubrutinib in combination with venetoclax.
SEQUOIA also showed that zanubrutinib was generally well tolerated. Previous data have highlighted that the therapy has
Results from the phase 3 ALPINE study,
“The combined clinical evidence from SEQUOIA, ALPINE, the 205 trial, and the AU-003 trial validates our confidence in Brukinsa as a regimen which can offer improvements in treatment outcomes for hundreds of thousands of patients living with CLL,” Jane Huang, MD, chief medical officer, hematology at BeiGene,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025
- Modest Reductions in PrEP Coverage Result in Avoidable HIV Infections
September 17th 2025